공시 • Feb 20
Eagle Veterinary Technology Co.,Ltd, Annual General Meeting, Mar 25, 2026 Eagle Veterinary Technology Co.,Ltd, Annual General Meeting, Mar 25, 2026, at 11:30 Tokyo Standard Time. Location: conference room, 235-34, chusa-ro, sinam-myeon, yesan-gun, chungcheongnam-do, South Korea 공시 • Dec 25
Eagle Veterinary Technology Co.,Ltd announced that it has received KRW 1.77621224 billion in funding On December 23, 2025. Eagle Veterinary Technology Co.,Ltd announces that it has closed the transaction. Upcoming Dividend • Dec 22
Upcoming dividend of ₩60.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 09 April 2026. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%). Reported Earnings • Nov 20
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: ₩10.5b (up 5.9% from 3Q 2024). Net income: ₩422.5m (up 128% from 3Q 2024). Profit margin: 4.0% (up from 1.9% in 3Q 2024). The increase in margin was driven by higher revenue. Declared Dividend • Nov 08
Dividend of ₩60.00 announced Dividend of ₩60.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 9th April 2026 Dividend yield will be 1.5%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 14% per year over the past 3 years and payments have been stable during that time. 공시 • Nov 07
Eagle Veterinary Technology Co.,Ltd announces Annual dividend, payable on April 09, 2026 Eagle Veterinary Technology Co.,Ltd announced Annual dividend of KRW 60.0000 per share payable on April 09, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. 공시 • Feb 13
Eagle Veterinary Technology Co.,Ltd, Annual General Meeting, Mar 19, 2025 Eagle Veterinary Technology Co.,Ltd, Annual General Meeting, Mar 19, 2025, at 11:30 Tokyo Standard Time. Location: conference room, 235-34, chusa-ro, sinam-myeon, yesan-gun, chungcheongnam-do, South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩40.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 17 April 2025. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%). Upcoming Dividend • Dec 20
Upcoming dividend of ₩40.00 per share at 0.7% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 17 April 2024. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.1%). New Risk • Oct 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (₩86.6b market cap, or US$64.0m). Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to ₩6,850, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to ₩7,070, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Negligible returns to shareholders over past three years. Upcoming Dividend • Dec 21
Inaugural dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. This is the first dividend for Eagle Veterinary TechnologyLtd since going public. The average dividend yield among industry peers is 1.0%. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩5,400, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 25% over the past three years. Upcoming Dividend • Dec 22
Inaugural dividend of ₩40.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 14 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Eagle Veterinary TechnologyLtd since going public. The average dividend yield among industry peers is 0.8%. Is New 90 Day High Low • Feb 23
New 90-day low: ₩8,060 The company is down 11% from its price of ₩9,010 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: ₩8,220 The company is down 7.0% from its price of ₩8,800 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. Valuation Update With 7 Day Price Move • Dec 25
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩9,370, the stock is trading at a trailing P/E ratio of 60.9x, down from the previous P/E ratio of 71.9x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 84%. Valuation Update With 7 Day Price Move • Dec 02
Market bids up stock over the past week After last week's 21% share price gain to ₩10,900, the stock is trading at a trailing P/E ratio of 70.9x, up from the previous P/E ratio of 58.6x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 103%. Is New 90 Day High Low • Dec 01
New 90-day high: ₩10,200 The company is up 9.0% from its price of ₩9,390 on 02 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Oct 12
New 90-day high: ₩9,730 The company is up 13% from its price of ₩8,620 on 14 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 13% over the same period.